StockWatch
·
Filing
Q3

J.B.CHEMICALS & PHARMACEUTICALS LTD.

JBCHEPHARMFY2504 Feb 2025
Revenue-3.7%
Net Profit-6.9%
OPM17.17%

P&L

Quarterly Consolidated

Revenue
-3.7%963.49
Expenditure
-2.6%753.50
Net Profit
-6.9%162.49
NPM 16.73%-3.1%EPS ₹10.46-6.9%

vs Q2 FY25

JB Pharma reports revenue growth of 14% to INR 963 crores in Q3 FY25, Net Profit increased by 22% to INR 162 crores

05 Feb 2025 · 5 Feb 2025, 12:26 am

Summary

JB Chemicals & Pharmaceuticals Itd (JB Pharma) has announced its financial results for the quarter ended 31st December 2024. The company reported a revenue of INR 963 crores, representing a 14% growth from INR 845 crores in Q3 FY24. The net profit increased by 22% to INR 162 crores from INR 134 crores in Q3 FY24. The operating EBITDA improved by 15% to INR 270 crores.

Key Highlights

  1. 1

    Revenue growth of 14% to INR 963 crores in Q3 FY25

  2. 2

    Net profit increased by 22% to INR 162 crores

  3. 3

    Operating EBITDA improved by 15% to INR 270 crores

  4. 4

    Domestic formulations business recorded revenue of INR 566 crores

  5. 5

    International business revenue grew by 4% at INR 397 crores

Management Comments

M

Mr. Nikhil Chopra

CEO and Wholetime Director, JB Pharma

JB has delivered consistent growth over last few years even amidst a volatile macroeconomic environment. This has been enabled by our mix of businesses and markets, specifically our focus on India branded formulations, CDMO, and select international markets which play to our strengths, with limited revenues in countries that might present trade-related or economic volatility challenges. JB is well-positioned to deliver continued growth going forward as well. The strategy and levers are well-defined, and we have a strong team that will execute. Our India business continues to drive market beating growth led by chronic business and progressive portfolio within the acute segment. Our export business continues to be steady with sequential improvement witnessed in our CDMO business.

Informational and educational content only. Not investment advice.